Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms

Blood

Volumn 127, Issue 24, 2016, Pages 3040-3053

  Emadali, Anouk ^a   Hoghoughi, Neda ^a   Duley, Samuel ^a   Hajmirza, Azadeh ^a   Verhoeyen, Els ^b,c,d   Cosset, Francois Loic ^b,c   Bertrand, Philippe ^e   Roumier, Christophe ^f   Roggy, Anne ^g   Suchaud Martin, Céline ^h   Chauvet, Martine ^a,h   Bertrand, Sarah ^a   Hamaidia, Sieme ^a,h   Rousseaux, Sophie ^a   Josserand, Véronique ^a   Charles, Julie ^a,h   Templier, Isabelle ^h   Maeda, Takahiro ⁱ   Bruder Costa, Juliana ^a,j   Chaperot, Laurence ^a,j   Plumas, Joel ^a,j   Jacob, Marie Christine ^a,h   Bonnefoix, Thierry ^a   Park, Sophie ^h   Gressin, Remy ^a,h   Tensen, Cornelis P ^k   Mecucci, Cristina ^l   Macintyre, Elizabeth ^m   Leroux, Dominique ^a,h   Brambilla, Elisabeth ^a   Nguyen Khac, Florence ⁿ   Luquet, Isabelle ^o   Penther, Dominique ^e   Bastard, Christian ^e   Jardin, Fabrice ^e   Lefebvre, Christine ^a,h   Garnache, Francine ^g   Callanan, Mary B ^a,h   more..

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^e UNIVERSITÉ DE ROUEN   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^j ETABLISSEMENT FRANÇAIS DU SANG   (France)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF PERUGIA   (Italy)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; GLUCOCORTICOID RECEPTOR; LONG UNTRANSLATED RNA; TRANSCRIPTION FACTOR EZH2; UNTRANSLATED RNA; NR3C1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUSION; GENE OVEREXPRESSION; GENE SEQUENCE; HAPLOINSUFFICIENCY; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NR3C1 GENE; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; CHEMISTRY; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TUMOR CELL CULTURE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DENDRITIC CELLS; GENE EXPRESSION REGULATION, LEUKEMIC; HAPLOINSUFFICIENCY; HUMANS; LEUKEMIA; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, GLUCOCORTICOID; RNA, LONG NONCODING; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84994052392     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-671040     Document Type: Article

References (67)

1. Fachetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: Press W, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:145-147.
2. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-1563.
3. Ramanathan M, Cerny J, Yu H, Woda BA, Nath R. A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2013;98(3):e36.
4. Roos-Weil D, Dietrich S, Boumendil A, et al; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
5. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-3217.
6. Osaki Y, Yokohama A, Saito A, et al. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One. 2013;8(11):e81722.
7. Petrella T, Comeau MR, Maynadié M,etal. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD561 precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-862.
8. Garnache-Ottou F, Feuillard J, Ferrand C, et al; GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
9. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
10. Jardin F, Callanan M, Penther D, et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009;23(4):698-707.
11. Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood. 2002;99(11):4154-4159.
12. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055-1061.
13. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011;153(3):413-416.
14. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
15. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+ CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-1727.
16. Sapienza MR, Fuligni F, Agostinelli C, et al; AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies' and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606-1616.
17. Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol. 2012;30(12):1343-1349.
18. Grimwade D, Walker H, Harrison G, et al; Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
19. Byrd JC, Mrózek K, Dodge RK, et al; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
20. Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523(7559):183-188.
21. Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509-520.
22. Varney ME, Niederkorn M, Konno H, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J Exp Med. 2015;212(11):1967-1985.
23. Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol. 2006;176(1):248-255.
24. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005;81(2):148-154.
25. Fournier A, McLeer-Florin A, Lefebvre C, et al. 1q12 Chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. EMBO Mol Med. 2010;2(5):159-171.
26. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26(16):2069-2070.
27. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
28. Gelsi-Boyer V, Trouplin V, AdélaïdeJ,etal. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
29. Emadali A, Rousseaux S, Bruder-Costa J, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med. 2013;5(8):1180-1195.
30. Vert JP, Foveau N, Lajaunie C, Vandenbrouck Y. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics. 2006;7:520.
31. Lévy C, Frecha C, Costa C, et al. Lentiviral vectors and transduction of human cancer B cells. Blood. 2010;116(3):498-500, author reply 500.
32. Lajmanovich A, Ribeyron JB, Florin A, et al. Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. Exp Cell Res. 2009;315(19):3281-3293.
33. Bonnefoix T, Callanan M. Accurate hematopoietic stem cell frequency estimates by fitting multicell Poisson models substituting to the single-hit Poisson model in limiting dilution transplantation assays. Blood. 2010;116(14):2472-2475.
34. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.
35. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
36. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010;75(1):1-12.
37. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377-1380.
38. Kuster L, Grausenburger R, Fuka G, et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117(9):2658-2667.
39. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242-252.
40. Goossens S, Radaelli E, Blanchet O, et al. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015;6:5794.
41. Schotte R, Nagasawa M, Weijer K, Spits H, Blom B. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. J Exp Med. 2004;200(11):1503-1509.
42. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-542.
43. Rhein P, Scheid S, Ratei R, et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia. 2007;21(5):897-905.
44. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741-750.
45. Takeda A, Goolsby C, Yaseen NR. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res. 2006;66(13):6628-6637.
46. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26-46.
47. Hashimoto M, Suizu F, Tokuyama W, et al. Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo. Oncogenesis. 2013;2:e70.
48. Wang Z, Iwasaki M, Ficara F, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell. 2010;17(6):597-608.
49. Chaluvally-Raghavan P, Zhang F, Pradeep S, et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014;26(6):863-879.
50. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785-797.
51. Georgantas RW III, Tanadve V, Malehorn M, et al. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 2004;64(13):4434-4441.
52. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2):369-381.
53. Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320-334.
54. Pastori C, Kapranov P, Penas C, et al. The bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci USA. 2015;112(27):8326-8331.
55. Paugh SW, Bonten EJ, Savic D, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015;47(6):607-614.
56. Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy [published online ahead of print January31, 2016]. Oncotarget.
57. Heuck CJ, Szymonifka J, Hansen E, et al. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clin Cancer Res. 2012;18(19):5499-5506.
58. John S, Sabo PJ, Thurman RE, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet. 2011;43(3):264-268.
59. Nixon M, Andrew R, Chapman KE. It takes two to tango: dimerisation of glucocorticoid receptor and its anti-inflammatory functions. Steroids. 2013;78(1):59-68.
60. Wu JN, Pinello L, Yissachar E, Wischhusen JW, Yuan GC, Roberts CW. Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia. Epigenetics Chromatin. 2015;8:53.
61. Schmitges FW, Prusty AB, Faty M, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell. 2011;42(3):330-341.
62. Tie F, Banerjee R, Stratton CA, et al. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development. 2009;136(18):3131-3141.
63. Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71(20):6360-6370.
64. Matthews LC, Berry AA, Morgan DJ, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy. Proc Natl Acad Sci USA. 2015;112(17):5479-5484.
65. Yemelyanov A, Czwornog J, Chebotaev D, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 2007;26(13):1885-1896.
66. Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell. 2015;58(6):1028-1039.
67. Devaiah BN, Case-Borden C, Gegonne A, et al. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin [published online ahead of print May 9, 2016]. Nat Struct Mol Biol. doi:10.1038/nsmb.3228.